CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 148 enrolled
Drug / intervention
Conization and/or Hysterectomyprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05267834
NCT05267834N/ACompleted

In Situ/Microinvasive Adenocarcinoma of the Uterine Cervix and HPV-type Impact: Pathologic Features, Treatment Options, and Follow-up Outcomes - Cervical Adenocarcinoma Study Group (CAS-Group).

Università Politecnica delle Marche·observational·Posted Mar 4, 2022·Updated Mar 24, 2023

In Brief

An observational study evaluating Conization and/or Hysterectomy for Adenocarcinoma of the Uterine Cervix. Completed, enrolled 148 participants across 1 site.

Detailed Summary

The present study will mainly aim to review and characterize the pathologic features, treatment options, and follow-up outcomes of women with in situ/microinvasive adenocarcinoma of the uterine cervix according to HPV status (positive versus negative high-risk HPV). It will evaluate the impact of HPV status on the recurrence and survival during a follow-up of five years. The present study will be a multi-institutional study including several oncological Italian Centers. Data will be retrospectively collected from January 2012 to December 2016 with a total follow-up of 5 years.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesItaly
Collaborators--

Timeline

N/ACompletedFinished
2023202420252026
First PostedMar 4, 2022
Enrollment StartJun 30, 2022
Primary CompletionMar 1, 2023
Study CompletionMar 20, 2023
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 4.3 years ago

Interventions

Conization and/or Hysterectomyprocedure

Women undergoing cervical conization or simple/modified/radical hysterectomy with or without pelvic lymphadenectomy